Cas:1922-48-1 3β-Hydroxy-16β-methyl-16α,17α-oxido-Δ5-pregnenon-20 manufacturer & supplier

Chemical Name:3β-Hydroxy-16β-methyl-16α,17α-oxido-Δ5-pregnenon-20

CAS.NO:1922-48-1

Synonyms:16alpha,17-Dihydroxypregn-4-ene-3,20-dione;Algestonum;ALGESTONE;Alphasone;Algestona

Molecular Formula:C₂₂H₃₂O₃

Molecular Weight:344.48800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:462.3ºC at 760 mmHg

Density:1.17g/cm3

Index of Refraction:1.572

PSA:49.83000

Exact Mass:344.23500

LogP:4.03670

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 16alpha,17-Dihydroxypregn-4-ene-3,20-dione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Algestona physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ALGESTONE Use and application,Alphasone technical grade,usp/ep/jp grade.

Related News: The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 3β-Hydroxy-16β-methyl-16α,17α-oxido-Δ5-pregnenon-20 manufacturer Pharmaceutical intermediates and APIs belong to the fine chemical industry. 3β-Hydroxy-16β-methyl-16α,17α-oxido-Δ5-pregnenon-20 supplier Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. 3β-Hydroxy-16β-methyl-16α,17α-oxido-Δ5-pregnenon-20 vendor The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 3β-Hydroxy-16β-methyl-16α,17α-oxido-Δ5-pregnenon-20 factory Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.